SS Innovations International, Inc. — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 58/100
What the filing says
SS Innovations reported Q2 2026 revenue of $13.9M (+39.4% YoY) and H1 2026 revenue of $25.0M (+65.6% YoY), driven by 30 SSi Mantra robotic system installations in Q2 and 56 in H1 (cumulative installed base now 224 systems across 12 countries). However, Q2 net loss widened to $2.7M from $0.3M YoY, and H1 net loss was $6.2M vs. $5.9M YoY, despite gross margin expansion to 50.9% in Q2. The company holds $13.6M cash (excluding restricted), zero long-term debt, and expects FDA 510(k) completion by Q1 2027 and EU CE marking by end-2026.
Why this rating
Strong revenue growth (65.6% H1) relative to $270M market cap is material, but widening net losses despite higher volumes and operating expense leverage signal execution risk. FDA/EU approvals could be transformational but remain uncertain forward-looking items.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.